| Juan Manuel Mercado, MD | |
|
61 Via Del Monte, Parque Del Monte, Trujillo Alto, PR 00976-6089 | |
| (787) 236-3918 | |
| Not Available |
| Full Name | Juan Manuel Mercado |
|---|---|
| Gender | Male |
| Speciality | General Practice |
| Location | 61 Via Del Monte, Trujillo Alto, Puerto Rico |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033411426 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208D00000X | General Practice | 18097 (Puerto Rico) | Primary |
| Entity Name | Signify Health Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689158487 PECOS PAC ID: 3274895263 Enrollment ID: O20210804002801 |
News Archive
Practice Fusion Inc. (www.practicefusion.com), the free, web-based electronic health record (EHR) for physicians, today implemented a first-of-its-kind tool that allows its physician-users to immediately and accurately identify all Tier 1 candidates for H1N1 vaccination from their patient populations using criteria published by the Centers for Disease Control and Prevention (CDC).
A research project at the Peninsula Medical School in Exeter, which will study the effect of hydrogen sulfide (H2S - the 'rotten eggs' gas) as an effective anti-inflammatory agent, has won a research grant of -140,000 over three years from the Wellcome Trust.
Scientists at Houston Methodist received support from the U.S. Department of Defense to reprogram cancer patients' immune cells to attack triple negative breast cancer, the most lethal form of breast cancer.
The United Kingdom government plans to implement mass scale population testing for SARS-CoV-2 infection using Lateral Flow Devices (LFDs), yet the devices' sensitivity is unknown
Alexion Pharmaceuticals, Inc. has announced today that Soliris® (eculizumab), its first-in-class complement inhibitor, has been granted Orphan Medicinal Product Designation by the European Commission for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS). AHUS is an ultra-rare, inherited, and life-threatening complement-inhibitor deficiency disease that often progresses to end-stage kidney disease or failure. The U.S. Food and Drug Administration granted orphan drug designation to Soliris for the same indication in May 2009. Soliris is not approved for the treatment of patients with aHUS.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Juan Manuel Mercado, MD 61 Via Del Monte, Parque Del Monte, Trujillo Alto, PR 00976-6089 Ph: (787) 236-3918 | Juan Manuel Mercado, MD 61 Via Del Monte, Parque Del Monte, Trujillo Alto, PR 00976-6089 Ph: (787) 236-3918 |
News Archive
Practice Fusion Inc. (www.practicefusion.com), the free, web-based electronic health record (EHR) for physicians, today implemented a first-of-its-kind tool that allows its physician-users to immediately and accurately identify all Tier 1 candidates for H1N1 vaccination from their patient populations using criteria published by the Centers for Disease Control and Prevention (CDC).
A research project at the Peninsula Medical School in Exeter, which will study the effect of hydrogen sulfide (H2S - the 'rotten eggs' gas) as an effective anti-inflammatory agent, has won a research grant of -140,000 over three years from the Wellcome Trust.
Scientists at Houston Methodist received support from the U.S. Department of Defense to reprogram cancer patients' immune cells to attack triple negative breast cancer, the most lethal form of breast cancer.
The United Kingdom government plans to implement mass scale population testing for SARS-CoV-2 infection using Lateral Flow Devices (LFDs), yet the devices' sensitivity is unknown
Alexion Pharmaceuticals, Inc. has announced today that Soliris® (eculizumab), its first-in-class complement inhibitor, has been granted Orphan Medicinal Product Designation by the European Commission for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS). AHUS is an ultra-rare, inherited, and life-threatening complement-inhibitor deficiency disease that often progresses to end-stage kidney disease or failure. The U.S. Food and Drug Administration granted orphan drug designation to Soliris for the same indication in May 2009. Soliris is not approved for the treatment of patients with aHUS.
› Verified 4 days ago
Dr. Vanessa Vega Hernandez, M.D. General Practice Medicare: Medicare Enrolled Practice Location: Plaza San Miguel Ste. 207, Carr 181 Bo. Las Cuevas, Trujillo Alto, PR 00976 Phone: 787-752-7184 Fax: 787-752-7184 | |
Dr. Huascar A Barros Burgos, MD General Practice Medicare: Medicare Enrolled Practice Location: 28 Calle Munoz Rivera, Trujillo Alto, PR 00976 Phone: 787-760-6604 Fax: 787-292-0130 | |
Dr. Cibeles Cotto, M.D. General Practice Medicare: Accepting Medicare Assignments Practice Location: 1 Ave. Periferal Cond. Ciudad Universitaria, Aptdo. G-008, Trujillo Alto, PR 00976 Phone: 787-755-2630 Fax: 787-755-2630 | |
Dr. Ruth E Rodriguez, M.D. General Practice Medicare: Not Enrolled in Medicare Practice Location: Bo. Dos Bocas, Carr. 181 Km. 9.1, Trujillo Alto, PR 00976 Phone: 787-760-5545 Fax: 787-760-5545 | |
Dr. Elba Antoinette Perez, M.D. General Practice Medicare: Medicare Enrolled Practice Location: Expreso Trujillo Alto Km 4.4, San Miguel Medical - Suite 204 Plaza San Miguel, Trujillo Alto, PR 00976 Phone: 787-748-7120 Fax: 787-748-7105 | |
Dr. Francisco Jose Machado Jr., M.D General Practice Medicare: Not Enrolled in Medicare Practice Location: 40 Paseo De Las Flores, Primavera-encantada, Trujillo Alto, PR 00976 Phone: 787-318-6946 Fax: 787-761-5934 |